Rocket Pharmaceuticals, Inc. (RCKT)
| Market Cap | 374.29M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -223.12M |
| Shares Out | 109.12M |
| EPS (ttm) | -2.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,750,207 |
| Open | 3.640 |
| Previous Close | 3.490 |
| Day's Range | 3.385 - 3.740 |
| 52-Week Range | 2.190 - 8.260 |
| Beta | 0.57 |
| Analysts | Buy |
| Price Target | 29.73 (+766.76%) |
| Earnings Date | May 4, 2026 |
About RCKT
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardia... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for RCKT stock is "Buy." The 12-month stock price target is $29.73, which is an increase of 766.76% from the latest price.
News
Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare ...
Rocket Pharmaceuticals Transcript: FDA announcement
FDA granted accelerated approval to KRESLADI, the first gene therapy for severe LAD-I in children. Launch is planned for Q4 2026 with initial treatments at a few specialized centers, and full approval will depend on ongoing patient follow-up and post-marketing data collection.
Rocket Pharma shares climb as FDA approves first therapy for deadly childhood disorder
Rocket Pharmaceuticals shares jumped 10% on Friday before the bell after the U.S. Food and Drug Administration approved its gene therapy for a rare and often fatal immune disorder in children, marki...
Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with hig...
Rocket Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026
Key cardiac gene therapy programs are advancing, with Danon and PKP2 trials progressing toward regulatory milestones in 2026. Commercial readiness for KRESLADI is set for March, and operational restructuring supports a focused rare cardiac pipeline. Manufacturing improvements and strategic patient selection are shaping clinical and commercial success.
Rocket Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
The session highlighted a strong cash position, a strategic focus on rare cardiac diseases, and key clinical milestones for KRESLADI, Danon, PKP2, and BAG3. Regulatory progress, trial design updates, and partnership opportunities were discussed, with a positive outlook on market potential and organizational evolution.
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord...
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord...
Rocket Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
Focused on advancing gene therapies for rare cardiovascular diseases, with Danon, PKP2, and BAG3 as lead programs. Strong long-term efficacy data, robust financial runway, and in-house manufacturing support execution. Anticipates key 2026 milestones, including Kresladi approval and pivotal trial progress.
Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord...
Rocket Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference
The company is prioritizing AAV-based cardiovascular gene therapies, with Danon, PKP2, and BAG3 as key programs. Danon trial restarts in 2026 after safety improvements, while Lenti-based programs shift to partnerships. Kresladi resubmission aims for March 28 approval.
Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord...
Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord...
FDA Acceptance Of Rocket Pharmaceuticals' Lead Gene Therapy Application Reestablishes Momentum For Stock
On Tuesday, the U.S. Food and Drug Administration (FDA) accepted Rocket Pharmaceuticals, Inc.'s (NASDAQ:RCKT) resubmission of the Biologics License Application (BLA) for Kresladi (marnetegragene autot...
Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord...
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord...
Rocket Pharmaceuticals withdraws US application of gene therapy for rare blood disorder
Rocket Pharmaceuticals said on Friday that it has withdrawn its application for U.S approval of its experimental gene therapy for a rare inherited blood disorder.
Rocket Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
The company is prioritizing its AAV-based cardiac gene therapy programs, with Danon Disease, PKP2, and BAG3 as key assets. Danon’s pivotal trial resumes in 2026 after safety adjustments, while PKP2 and BAG3 advance toward pivotal and phase one trials, respectively. Key regulatory and data updates are expected over the next 12–18 months.
Rocket Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025
The cardiac gene therapy portfolio is advancing, with Danon disease trials resuming after FDA hold lift and protocol refinements to enhance safety. Enrollment for pivotal Danon patients is targeted for early 2026, while PKP2 and BAG3 programs progress with lessons learned from Danon.
Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.
The past year has been a disappointing one for gene therapies.
FDA Lifts Rocket Pharmaceuticals Study Hold For Rare Disease Gene Therapy
Rocket Pharmaceuticals Inc. RCKT stock is trading higher on Wednesday after the U.S. Food and Drug Administration (FDA) lifted the clinical hold on its pivotal Phase 2 trial of RP-A501 for Danon disea...
US FDA lifts clinical hold on Rocket Pharmaceuticals' gene therapy trial
Rocket Pharmaceuticals said on Wednesday that the U.S. Food and Drug Administration has lifted the clinical hold on its gene therapy mid-stage trial.
Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord...
DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025
PHILADELPHIA , Aug. 8, 2025 /PRNewswire/ -- Berger Montague PC , a leading Philadelphia-based law firm representing investors, announces that a securities class action lawsuit has been filed against ...
Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disord...